...
首页> 外文期刊>Investigative ophthalmology & visual science >Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy.
【24h】

Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy.

机译:Arpc1b基因是对放射疗法敏感的脉络膜恶性黑色素瘤的候选预测标记。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: Choroidal malignant melanomas (CMMs) are the most common primary intraocular tumors in adult humans. Although radiotherapy is commonly used to treat the melanomas, the therapeutic effects are unpredictable. The purpose of this study was to search for a gene(s) that can predict the success of radiotherapy for CMMs. METHODS: The cell lines 92-1, OCM-1, and OMM-1 were established from patients with CMM, and radiation sensitivity was determined using the colony-formation assay. RNA was extracted from nonirradiated cells, and gene expression analysis was performed using a microarray containing 10,800 genes. The up- or downregulated genes were verified by real-time PCR using other cancerous cell lines in which radiation sensitivity had been documented. RESULTS: Analysis of radiation survival curves showed that cell line 92-1 was radiation sensitive and OCM-1 and OMM-1 lines were radiation resistant. The results of microarray analyses showed that 34 genes were differentially expressed in the OCM-1 and OMM-1 cell lines compared with the 92-1 cell line. The validity of the expression level of 13 of the 34 genes that were identified by microarray was confirmed by PCR. From the analysis of the different radio-sensitivity cancer cell lines, the Arpc1b gene was selected as a prediction marker gene for sensitivity of CMM to radiotherapy. CONCLUSIONS: Gene expression analysis of CMM cell lines can be used to search for radiation sensitivity prediction markers. Comprehensive gene expression profiles of radiation-sensitive and/or resistant cell lines may provide new insights into the mechanisms of resistance or sensitivity to radiation therapy.
机译:目的:脉络膜恶性黑色素瘤(CMM)是成年人中最常见的原发性眼内肿瘤。尽管放疗通常用于治疗黑色素瘤,但治疗效果是不可预测的。这项研究的目的是寻找可以预测CMM放射治疗成功的基因。方法:从患有CMM的患者中建立细胞系92-1,OCM-1和OMM-1,并使用集落形成测定法确定放射敏感性。从未经辐照的细胞中提取RNA,并使用包含10,800个基因的微阵列进行基因表达分析。上调或下调的基因通过实时PCR验证,使用了已证明有放射敏感性的其他癌细胞系。结果:辐射存活曲线分析表明,细胞系92-1对辐射敏感,OCM-1和OMM-1细胞系具有抗辐射能力。微阵列分析的结果表明,与92-1细胞系相比,OCM-1和OMM-1细胞系中有34个基因差异表达。通过PCR确认了通过微阵列鉴定的34个基因中的13个基因的表达水平的有效性。通过对不同放射敏感性癌细胞系的分析,选择Arpc1b基因作为CMM对放射治疗敏感性的预测标记基因。结论:CMM细胞系的基因表达分析可用于搜索辐射敏感性预测标记。辐射敏感和/或耐药细胞系的全面基因表达谱可提供对辐射疗法耐药或敏感性机制的新见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号